TuHURA Biosciences (NASDAQ: HURA) reported its fourth‑quarter and full‑year 2025 financial results on April 1 2026. The company posted a net loss of $0.13 per share, in line with analyst expectations, and a cash balance of $3.6 million at year‑end. A registered direct offering in the first quarter of 2026 added $7.5 million, bringing total liquidity to $11.1 million.
Research and development expenses rose to $20.5 million in 2025, up 54% from $13.3 million in 2024, reflecting intensified investment in the company’s lead immuno‑oncology asset, IFx‑2.0, and the newly acquired TBS‑2025 program from Kineta. General and administrative costs more than doubled to $7.6 million from $3.9 million, largely due to integration expenses and expanded support for the growing clinical portfolio.
Operating cash outflows increased to $27.7 million, a 88% jump from $14.7 million in 2024, underscoring the high burn rate typical of a pre‑revenue biotech. The company’s cash runway is therefore limited, and the recent capital raise is critical to fund ongoing Phase 3 trials and future development milestones.
Clinically, the company announced the appointment of Dr. Craig Tendler as Chief Medical Officer, a move aimed at accelerating the IFx‑2.0 Phase 3 trial for Merkel cell carcinoma. Enrollment is now expected to complete in mid‑2027, and the company’s focus remains on this single high‑potential asset. The acquisition of Kineta and its TBS‑2025 program expands TuHURA’s pipeline into the VISTA checkpoint space, providing a secondary development path.
The announcement was well received by investors, reflecting confidence in the company’s clinical strategy and recent progress. The company’s regained Nasdaq compliance in February 2026 and the appointment of experienced clinical leadership further bolstered market sentiment.
Looking ahead, TuHURA’s high burn rate and limited cash position highlight the need for additional financing to sustain its clinical program. The company’s focus on a single, high‑potential asset, coupled with strategic acquisitions, positions it to potentially generate significant upside if the Phase 3 trial succeeds, but the continued reliance on external capital remains a key risk factor.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.